We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (GBIO) (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, ...
70% of circulating and splenic T cells positive for mRNA expression in humanized mice with less than 8% delivery to off-target immune cells Stealth properties of cell-targeted lipid nanoparticle ...
Wedbush analyst David Nierengarten on Wednesday downgraded Generation Bio (GBIO) to ‘Neutral’ from ‘Outperform’ with a $7 price target after the company announced a strategic restructuring. Shares of ...
Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:GBIO), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...
CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune ...
Hosted on MSN
Xoma to acquire Generation Bio for $4.2913 per share
Xoma Royalty (XOMA) announced it has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share at the closing of the merger. Generation Bio stockholders also ...
New non-human primate data show highly selective in vivo delivery of mRNA to T cells with a cell-targeted lipid nanoparticle (ctLNP) The company presented data showing that a single IV dose of its ...
After Generation Bio telegraphed plans to lay off 90% of its staff this summer, Xoma Royalty has come knocking to bring yet another ailing biotech into its fold. Xoma, which styles itself as a ...
• New data confirm highly selective profile of cell-targeted lipid nanoparticle (ctLNP) and first-ever siRNA delivery to T cells in non-human primates • Lead siRNA candidates show potent knockdown of ...
Generation Bio is a biotechnology company aiming to treat autoimmune disorders by delivering gene-silencing molecules to T cells, a specific type of immune cell. Its platform centers on a proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results